Travere, CSL Gets Standard EU Approval for Kidney Disorder Treatment
Express News | CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy
CSL Vifor and Travere Therapeutics Announce Standard EU Approval for FILSPARI in IgA Nephropathy
Earnings Preview: TVTX to Report Financial Results Post-market on May 01
Press Release: Travere Therapeutics to Report First Quarter 2025 Financial Results
Travere Therapeutics, Inc. (NASDAQ:TVTX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Scotiabank Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Cuts Target Price to $30
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $47
Guggenheim Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $47
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
Cantor Fitzgerald Maintains Travere Therapeutic(TVTX.US) With Buy Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Travere Therapeuticsto Overweight
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $31
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Travere Therapeutics Is Maintained at Buy by B of A Securities
Express News | Travere Therapeutics Inc : BofA Global Research Raises Price Objective to $31 From $29
Travere Therapeutics Announces It Will Present Three Abstracts, Including One Late-Breaking Oral Presentation, At Upcoming National Kidney Foundation Spring Clinical Meetings 2025, Taking Place April 10-13 In Boston, MA
Express News | Travere Therapeutics Shares up 4.8% After Co Submits US Marketing Application to the FDA for Kidney Disease Treatment
Express News | Travere Therapeutics Inc: Continues to Expect a Rems Modification Pdufa Target Action Date of August 28